Cilostazol for Prevention of Recurrent Stroke Trial

Last updated: September 12, 2025
Sponsor: Stanford University
Overall Status: Active - Not Recruiting

Phase

3

Condition

Myocardial Ischemia

Coronary Artery Disease

Heart Disease

Treatment

Placebo

Cilostazol 100 mg

Clinical Study ID

NCT07174414
82476
1UG3NS133209-01A1
  • Ages > 40
  • All Genders

Study Summary

The goal of this clinical trial is to learn whether adding cilostazol to aspirin or clopidogrel prevents stroke and heart attack in people who have had a stroke or mini-stroke.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of stroke or mini-stroke (also called TIA) within the last 180 days

  • Currently taking aspirin or clopidogrel (not both) to prevent another stroke

Exclusion

Exclusion Criteria:

  • Had a spontaneous brain bleed within the last 2 years.

  • Moderate to severe heart failure.

  • Life expectancy is less than 6 months.

Study Design

Total Participants: 2000
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 3
Study Start date:
August 01, 2026
Estimated Completion Date:
July 31, 2031

Connect with a study center

  • Stanford University

    Stanford 5398563, California 5332921 94305
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.